<DOC>
	<DOC>NCT02385136</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety profile and efficacy of whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ) in patients with brain metastases (BM).Patients with BM were randomly assigned to 30 Gy of WBRT with or without concomitant TMZ (75 mg/m2/d) plus two cycles of TMZ (200 mg/m2/d for 5 days).</brief_summary>
	<brief_title>Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>histologically diagnosed as NSCLC, stage IVb [ (American Joint of Cancer Committee(AJCC), 2002) ], Brain metastasis no history of hypertension or diabetes. the brain tumor diameter &gt;5cm; RPA class =3; pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Radiotherpy</keyword>
	<keyword>Temozolomide</keyword>
</DOC>